Compare Moody's Corporation (MCO) vs Merck & Co., Inc. (MRK) Price & Performance

Moody's CorporationTrade

Merck & Co., Inc.Trade

Price performance (Past 24H)

Key statistics

Moody's Corporation vs Merck & Co., Inc. — how do they compare? Moody's Corporation trades at $477 (market cap $82.52B), while Merck & Co., Inc. trades at $129.69 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 3.9× Moody's Corporation's market cap, and Merck & Co., Inc. pays the higher dividend (2.61%). Which is the better fit depends on your goals.

	MCO	MRK
Market Cap	$82.52B	$321.77B
Sector	Financials	Health
52-Week High	$539.61	$131.84
52-Week Low	$412.23	$77.60
Enterprise Value	$88.54B	$368.53B
Dividend Yield	0.86%	2.61%

View details →View details →

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moody's Corporation

No Aura AI signal available yet.

Merck & Co., Inc.

Merck (MRK) trades at $130.9, up 1.81% today, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $140.36. Recent earnings beats and a 72.97% gross margin highlight strong profitability, while the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline. The stock faces headwinds from a high P/E ratio of 104.34 and fluctuating cash flows.

The outlook is positive with robust fundamentals and strategic M&A, but valuation concerns and competitive pressures in pharma pose risks. Upside is likely if earnings growth continues, though investors should monitor debt levels and integration of acquisitions.

Aura AI is an analytical signal, not financial advice — do your own research.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

MCO

iShares U.S. Broker-Dealers ETF seen as a buy despite recent underperformance and market volatility.Seeking Alpha · 2 days agoBullish View details →

MRK

Revolution Medicines hits $44B market cap with breakthrough RAS cancer drugs, attracting big pharma interest.24/7 Wall Street · 4 hours agoBullish Bio-Techne reports flat FY2026 revenue, EPS rise, and confirms $11.3B acquisition by Merck KGaA.PRNewsWire · 6 hours agoBullish Trump orders splitting MMR vaccine into three shots despite no scientific support and expert criticism.CNBC · 1 day agoBearish View details →

About Moody's Corporation

Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.